Showing results (371-380 of 631,695) with videos related to
Sort By:
Pageof 63,170
Recent Patents on Biotechnology|March 11, 2016
Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian CancerChristopher J LaFargue, Krishnansu S TewariIndian Journal of Anaesthesia|August 11, 2017
Perioperative management of patients with severe hypophosphataemia secondary to oncogenic osteomalacia: Our experience and review of literatureAlka Verma, Saipriya Tewari, Ashish KannaujiaGynecologic Oncology|October 15, 2020
The current landscape of molecular profiling in the treatment of epithelial ovarian cancerCarolyn E Haunschild, Krishnansu S TewariACS Infectious Diseases|September 20, 2019
Antagonistic Interaction of Staphylococcus aureus and Staphylococcus epidermidis with Rhizopus arrhizus Mediated by Phenol Soluble Modulins and Organic AcidsAnjna Kumari, Rupinder Tewari, Rachna SinghExpert Review of Anticancer Therapy|October 18, 2016
The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancerLindsey E Minion, Krishnansu S TewariClinical Advances in Hematology & Oncology : H&O|April 12, 2017
Manifestations and management of veno-occlusive disease/sinusoidal obstruction syndrome in the era of contemporary therapiesPriti Tewari, Whitney Wallis, Partow KebriaeiClinical Advances in Hematology & Oncology : H&O|February 4, 2022
Current and emerging immunotherapies for recurrent cervical cancerMarisa C Liu, Krishnansu S TewariExpert Review of Clinical Pharmacology|July 3, 2014
PARP inhibition and synthetic lethality in ovarian cancerRamez N Eskander, Krishnansu S TewariProceedings of the National Academy of Sciences of the United States of America|August 1, 1974
Conservation of 70S ribosomal RNA genes in the chloroplast DNAs of higher plantsJ R Thomas, K K TewariExpert Opinion on Pharmacotherapy|February 4, 2015
Integration of bevacizumab with chemotherapy doublets for advanced cervical cancerLauren S Krill, Krishnansu S TewariPageof 63,170